Differences in the Treatment of Benign Prostatic Hyperplasia: Comparing the Primary Care Physician and the Urologist-Reference-Cited by-同舟云学术

Differences in the Treatment of Benign Prostatic Hyperplasia: Comparing the Primary Care Physician and the Urologist

Published:2017-05 Issue:3 Volume:4 Page:193-199
ISSN:2352-0779
Container-title:Urology Practice
language:en
Short-container-title:Urology Practice

Author:

Rensing Adam J.¹,Kuxhausen Adrienne¹,Vetter Joel¹,Strope Seth A.¹

Affiliation:

1. Division of Urologic Surgery, Washington University School of Medicine, St. Louis, Missouri

Publisher

Ovid Technologies (Wolters Kluwer Health)

Subject

Urology

Reference16 articles.

1. Urologic Diseases in America project: benign prostatic hyperplasia;Wei;J Urol,2008

2. BPH: costs and treatment outcomes;Nickel;Am J Manag Care,2006

3. A randomized, placebo-controlled multicenter study of the efficacy and safety of terazosin in the treatment of benign prostatic hyperplasia;Lepor;J Urol,1992

4. The long-term effect of doxazosin, finasteride, and combination therapy on the clinical progression of benign prostatic hyperplasia;McConnell;N Engl J Med,2003

5. The effects of combination therapy with dutasteride and tamsulosin on clinical outcomes in men with symptomatic benign prostatic hyperplasia: 4-year results from the CombAT study;Roehrborn;Eur Urol,2010

Cited by 8 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Management Patterns for Benign Prostatic Hyperplasia: Impact of a Patient Decision Aid;Urology Practice;2021-07

2. Real‐world therapeutic management and evolution of patients with benign prostatic hyperplasia in primary care and urology in Spain;International Journal of Clinical Practice;2021-05-29

3. Real‐world assessment and characteristics of men with benign prostatic hyperplasia (BPH) in primary care and urology clinics in Spain;International Journal of Clinical Practice;2020-08-16

4. Blasenentleerungsstörung auf dem Boden einer gutartigen Prostatavergrößerung (BPO);Aktuelle Urologie;2018-12

5. Phosphodiesterase inhibitors for lower urinary tract symptoms consistent with benign prostatic hyperplasia;Cochrane Database of Systematic Reviews;2018-11-16